About Us

Transforming breast density measurement.

Micrima has developed a new and innovative device to measure breast tissue properties.

Micrima is transforming the detection of breast cancer for all women, making a difference in the early diagnosis of breast cancer. The Mi~Scan device produces a BI-RADS breast density score in one minute, without ionising radiation or breast compression. This density output can be used pre-imaging to inform optimum imaging technique selection. Density scores can also be integrated into risk profiling models to aid in risk profiling from a younger age.

Our Mission is to detect more instances of breast cancer, earlier

Meet some of the team

“I’m really encouraged by the progress being made. I think you’ve really understood the challenges and got clear thinking about where you need to go”

— Richard Sidebottom, Royal Marsden NHS Trust, Micrima Clinical Advisory Board

Our journey so far…

  • Starting at Bristol University

    Originally based on technology developed for the detection of non-ferrous landmines, the early application to breast imaging was spun-out from the University of Bristol in 2005. The company founders, Roy Johnson, Professor Alan Preece and Professor Ian Craddock recognised the impact that such a technology could potentially have on breast cancer detection, resulting in the formation of the business now known as Micrima.

  • The development of Mi~Scan®

    We are currently conducting a clinical trial using our device in clinic. We expect to obtain CE marking under MDR by Q2 2025.

  • Product Commercialisation

    The new handheld and portable Mi~Scan tissue measurement device was announced in February 2024. This device is expected to be available for order from October 2024, with first shipments in 2025.